OncLive TV

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer.

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses effective prostate cancer screening methods and when to use active surveillance.

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.

Lori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses the benefits associated with robotic surgery in the treatment of patients with prostate cancer.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the phase III trial for extended letrozole (Femara) therapy for patients with breast cancer.

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the history of chimeric antigen receptor (CAR) T-cell therapy.

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses novel agents or clinical trials in development designed to help guide treatment decisions for patients with prostate cancer.

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Samuel Smith, PhD, university academic fellow at the University of Leeds, discusses a breast cancer prevention trial that measured adherence to preventative medication in women experiencing menopausal symptoms.

Hatem Soliman, MD, associate member of The Center for Women’s Oncology at the Moffitt Cancer Center discusses the prospective registry IMPACt study, which measured the impact of the MammaPrint 70-gene Breast Cancer Recurrence Assay in the routine management of women with early-stage breast cancer.

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.

Scott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.

Raphael Bueno, MD, chief, Division of Thoracic Surgery co-director, Brigham and Women’s Lung Center, vice chairman of Surgery for Cancer and Translational Research, professor at Harvard Medical School, discusses gene expression signatures for squamous cell lung carcinoma.

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.

Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.